0001104659-24-030070.txt : 20240301 0001104659-24-030070.hdr.sgml : 20240301 20240301173918 ACCESSION NUMBER: 0001104659-24-030070 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240229 FILED AS OF DATE: 20240301 DATE AS OF CHANGE: 20240301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Golembiewski Michael Joseph CENTRAL INDEX KEY: 0001639479 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22245 FILM NUMBER: 24711882 MAIL ADDRESS: STREET 1: 7 TURTLE CT CITY: FLEMINGTON STATE: NJ ZIP: 08822 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001017491 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 870449967 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646) 293-2100 MAIL ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC. DATE OF NAME CHANGE: 20100914 FORMER COMPANY: FORMER CONFORMED NAME: NEXMED INC DATE OF NAME CHANGE: 19970311 4 1 tm247762-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-02-29 0 0001017491 SEELOS THERAPEUTICS, INC. SEEL 0001639479 Golembiewski Michael Joseph C/O SEELOS THERAPEUTICS, INC. 300 PARK AVENUE, 2ND FLOOR NEW YORK NY 10022 0 1 0 0 Chief Financial Officer 0 Common Stock 2024-02-29 5 A 0 E 417 1.097 A 86869 D These shares were acquired under the Company's 2020 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Effective on November 28, 2023, the Issuer conducted a reverse stock split at a ratio of 1-for-30 (the "Reverse Split"). The number of shares reported herein reflects the number of shares after the Reverse Split. /s/ Michael Golembiewski 2024-03-01